Identification of Monosaccharide Derivatives as Potent, Selective, and Orally Bioavailable Inhibitors of Human and Mouse Galectin-3
作者:Chunjian Liu、Prasada Rao Jalagam、Jianxin Feng、Wei Wang、Thiruvenkadam Raja、Mallikarjuna Reddy Sura、Raju K. V. L. P. Manepalli、Bheema Reddy Aliphedi、Santosh Medavarapu、Satheesh K. Nair、Vetrichelvan Muthalagu、Ramesh Natesan、Anuradha Gupta、Brett Beno、Manoranjan Panda、Kaushik Ghosh、Jinal Kaushikkumar Shukla、Harinath Sale、Priyanka Haldar、Narasimharaju Kalidindi、Devang Shah、Dipal Patel、Arvind Mathur、Bruce A. Ellsworth、Dong Cheng、Alicia Regueiro-Ren
DOI:10.1021/acs.jmedchem.2c00517
日期:2022.8.25
novel series of monosaccharide-based, highly potent, and orally bioavailable inhibitors of human and mouse Gal-3. The novel monosaccharide derivatives proved to be selective for Gal-3, the only member of the chimeric type of galectins, over Gal-1 and Gal-9, representative of the prototype and tandem-repeat type of galectins, respectively. The proposed binding mode for the newly identified ligands was
Galectin-3 (Gal-3) 是 β-半乳糖苷结合蛋白家族的成员,与多种人类疾病有关。鉴定具有正确组合效力(针对人和小鼠 Gal-3)和药代动力学特性的 Gal-3 抑制剂,以充分评估 Gal-3 用于治疗干预的潜力,由于其结合口袋的特性,一直是一项重大挑战:人 Gal-3 和小鼠直系同源物之间的高亲水性和关键结构差异。我们报告了一系列新的基于单糖的、高效的和口服生物可利用的人和小鼠 Gal-3 抑制剂的发现。新的单糖衍生物被证明对 Gal-3 具有选择性,Gal-3 是嵌合型半乳凝素的唯一成员,优于 Gal-1 和 Gal-9,分别代表原型和串联重复类型的半乳凝素。新鉴定的配体的拟议结合模式通过与 Gal-3 蛋白结合的代表性类似物的 X 射线共晶结构得到证实。